A Comprehensive Approach to Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Annalice Gandini(Ospedale Policlinico San Martino), Alessandro Pastorino(Ospedale Policlinico San Martino), Stefania Sciallero(Ospedale Policlinico San Martino), V. Andretta(Ospedale Policlinico San Martino), Valentino Martelli(Ospedale Policlinico San Martino), Silvia Puglisi(Ospedale Policlinico San Martino), Danila Comandini(Ospedale Policlinico San Martino), Serafina Mammoliti(Ospedale Policlinico San Martino), Malvina Cremante(Ospedale Policlinico San Martino), Annamaria Pessino(Ospedale Policlinico San Martino), Massimiliano Grassi(Ospedale Policlinico San Martino), Giuseppe Fornarini(Ospedale Policlinico San Martino), Chiara Pirrone(Ospedale Policlinico San Martino), Alberto F. Sobrero(Ospedale Policlinico San Martino), Francesco Caprioni(Ospedale Policlinico San Martino)
Cancers
January 20, 2025
10.3390/cancers17020330
Cited by 8

Related Papers

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|The Lancet Oncology|2020|333
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
|˜The œLancet. Gastroenterology & hepatology|2020|249
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
|The Lancet Oncology|2021|148
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
|The Oncologist|2018|144